spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Marshall Edwards 

 HSMN NewsFeed - 5 Feb 2016
Novogen Announces Changes to the Board with New Chairman and Deputy Chairman Appointed
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 Jun 2011
Marshall Edwards Adds Former Genentech Head of Medical Affairs Robert Mass as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 17 Jun 2010
Marshall Edwards Announces Additional Management Changes With Appointment of New Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 26 Apr 2010
Marshall Edwards Appoints New President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Feb 2009
Novogen to Focus on Oncology Program
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Jan 2009
Marshall Edwards, Inc. Granted IND for Triphendiol
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Oct 2007
European Symposium Focuses on Phenoxodiol as an Investigational Drug for Ovarian Cancer Management
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Oct 2007
European Symposium on Phenoxodiol as an Investigational Drug for Ovarian Cancer Management
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Aug 2007
A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Aug 2007
First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Dr. Graham Kelly Retires as Director, Marshall Edwards, Inc.
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Jun 2007
OVArian TUmor REsponse ('OVATURE') Trial Enrolls First U.S. Patient
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 May 2007
New Research Results Show That Investigational Drug Phenoxodiol Targets Cancer Protein, Causing Cancer Cell Death
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Mar 2007
New Board Appointment at Marshall Edwards, Inc.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Dec 2006
Marshall Edwards, Inc. Announces Initial Trial Sites, Principle Investigator for Phase III OVATURE Trial for Phenoxodiol
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Nov 2006
Marshall Edwards, Inc. Appoints Professor Bryan Williams as Chairman
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Nov 2006
First Patient Treated in Phase III Ovarian Cancer Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Aug 2006
Novogen Cash Reserves $25.4M, Phenoxodiol Receives US FDA Clearance for Phase III Human Trial
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 May 2006
Marshall Edwards Achieves Special Protocol Assessment and Agreement With FDA on Phase III (Ovature Study) of Phenoxodiol as a Chemosensitizing Agent in Women With Platinum-Resistant Ovarian Cancer
Biopharmaceuticals Oncology FDA
Return to NewsFeed  

 Additional items found! 15

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 15 additional stories matching:
Marshall Edwards
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.